The Washington Post's story this week on how Pfizer opted out of pursuing a link between one of its blockbuster drugs and Alzheimer's prevention may have been overblown, Derek Lowe writes in Science Translational Medicine's blog.
The state of play: Undertaking an Alzheimer's trial is a huge endeavor, Lowe argues, and is both risky and expensive. "The clinical success rate for Alzheimer's trials is arguably zero per cent," he writes.